Abstract
Cancer cell metabolism plays an important role in the progression of lung cancer. It is characterized through a shift from an oxidative to a glycolytic bioenergetics pathway, a phenomenon referred to as the warburg effect. However, the deregulation of miRNAs contributing to the warburg effect and to cancer cell metabolism is still unknown. In the present study, the results demonstrate that the expression of miR-202 is significantly decreased, and it induces a metabolic shift in lung cancer cells. miR-202 exerts this function through targeting HK2, resulting in the increase of glucose uptake and lactate production. The altered metabolism induced by miR-202 leads to cancer cell growth. These studies demonstrated that miR-202 may be involved in the metabolic shift via targeting HK2 in lung cancer cells.
Keywords: HK2, lung cancer, miR-202.
Graphical Abstract
Current Signal Transduction Therapy
Title:miR-202 Mediates Metabolic Shift in Lung Cancer Cells via Targeting HK2
Volume: 9 Issue: 2
Author(s): Jin Li, Baohua Zhang, Qihuang Chen and Qiang Li
Affiliation:
Keywords: HK2, lung cancer, miR-202.
Abstract: Cancer cell metabolism plays an important role in the progression of lung cancer. It is characterized through a shift from an oxidative to a glycolytic bioenergetics pathway, a phenomenon referred to as the warburg effect. However, the deregulation of miRNAs contributing to the warburg effect and to cancer cell metabolism is still unknown. In the present study, the results demonstrate that the expression of miR-202 is significantly decreased, and it induces a metabolic shift in lung cancer cells. miR-202 exerts this function through targeting HK2, resulting in the increase of glucose uptake and lactate production. The altered metabolism induced by miR-202 leads to cancer cell growth. These studies demonstrated that miR-202 may be involved in the metabolic shift via targeting HK2 in lung cancer cells.
Export Options
About this article
Cite this article as:
Li Jin, Zhang Baohua, Chen Qihuang and Li Qiang, miR-202 Mediates Metabolic Shift in Lung Cancer Cells via Targeting HK2, Current Signal Transduction Therapy 2014; 9 (2) . https://dx.doi.org/10.2174/1574362410666150107234535
DOI https://dx.doi.org/10.2174/1574362410666150107234535 |
Print ISSN 1574-3624 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-389X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Monitoring Cell Therapy Using Iron Oxide MR Contrast Agents
Current Pharmaceutical Biotechnology The Place of the Bioisosteric Sila-Substitution in Drug Design
Drug Design Reviews - Online (Discontinued) Anti-Proliferative Effects of Novel Glyco-Lipid-Arsenicals (III) on MCF-7 Human Breast Cancer Cells
Medicinal Chemistry Targeting the Wingless Signaling Pathway with Natural Compounds as Chemopreventive or Chemotherapeutic Agents
Current Pharmaceutical Biotechnology Notch Signaling Proteins: Legitimate Targets for Cancer Therapy
Current Protein & Peptide Science Destabilizing Aneuploidy by Targeting Cell Cycle and Mitotic Checkpoint Proteins in Cancer Cells
Current Drug Targets Synthesis and Anticancer Activity of 2-Aryl-6-diethylaminoquinazolinone Derivatives
Letters in Drug Design & Discovery Clinical Impact of the Detection of BRAF Mutations in Thyroid Pathology: Potential Usefulness as Diagnostic, Prognostic and Theragnostic Applications
Current Medicinal Chemistry The Role of Diabetes in Molecular Pathogenesis of Cancer
Current Signal Transduction Therapy Lipid based Nanocapsules: A Multitude of Biomedical Applications
Current Pharmaceutical Biotechnology ADAM19/Adamalysin 19 Structure, Function, and Role as a Putative Target in Tumors and Inflammatory Diseases
Current Pharmaceutical Design Adipokines, Metabolism and the Immune Response in the Regulation of Inflammation
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Peptide-Based Anticancer Vaccines: Recent Advances and Future Perspectives
Current Medicinal Chemistry Human Carbonyl Reductases
Current Drug Metabolism Targeted Drugs and Nanomedicine: Present and Future
Current Pharmaceutical Design Role of Plasmacytoid Dendritic Cells in Lung-Associated Inflammation
Recent Patents on Inflammation & Allergy Drug Discovery Monoclonal Antibodies in Clinical Oncology
Anti-Cancer Agents in Medicinal Chemistry Structural Biology Insight for the Design of Sub-type Selective Aurora Kinase Inhibitors
Current Cancer Drug Targets Effect of Contrast-enhanced Contemporaneous <sup>18</sup>F-FDG PET/CT on Semi Quantification Uptake Value Using Third Party Viewing Workstation
Recent Patents on Medical Imaging New Insights on the Possible Role of Mast Cells in Aspirin-Induced Asthma
Current Molecular Pharmacology